Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy

Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00367562

Enrollment

Registered

2006-08-23

Start date

1996-01-31

Completion date

2005-12-31

Last updated

2006-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IGA Nephropathy

Keywords

IGA NEPHROPATHY, STEROIDS, ENALAPRIL, VALSARTAN, PROTEINURIA, IMMUNOGLOBULIN A NEPHROPATHY (IGA NEPHROPATHY)

Brief summary

TO ASSESS THE EFFICACY OF THE RENIN ANGIOTENSIN SYSTEM PLUS STEROIDS TO DECREASE THE AMOUNT OF PROTEINURIA IN IGA NEPHROPATHY

Detailed description

Patients whose proteinuria was \> 0.5 g/day were to receive enalapril plus valsartan coupled with oral 0.5 g/day of methylprednisone for 6 months.

Interventions

DRUGENALAPRIL VALSARTAN METHYLPREDNISONE

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

21 Years to 70 Years

Healthy volunteers

Inclusion criteria

* PATIENTES WITH IGA NEPHROPATHY WITH PROTEINURIA OVER 0.5 G/DAY

Exclusion criteria

* MALIGNANCY, RENAL FAILURE

Design outcomes

Primary

Measure	Time frame
DAILY PROTEINURIA	—

Secondary

Measure	Time frame
RENAL FUNCTION AS ASSESSED BY SERUM CREATININE	—

Countries

Argentina

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026